View Older Stories

Mar 25, 2026 04:11PM Beam Therapeutics Inc (BEAM) PT Raised to $68 at Citi

Mar 25, 2026 01:09PM Beam Therapeutics Inc (BEAM) PT Raised to $47 at Leerink Partners

Mar 25, 2026 01:00PM Clear Street on Beam Therapeutics Inc (BEAM): muted reaction is 'buying opportunity'

Mar 25, 2026 12:57PM William Blair stays Outperform on Beam Therapeutics Inc (BEAM) after "decisive validation' of BEAM-302 profile

Mar 25, 2026 11:48AM RBC on Beam Therapeutics Inc (BEAM): 'we view the data as incrementally positive'

Mar 3, 2026 07:21AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Feb 26, 2026 05:52AM Beam Therapeutics Inc (BEAM) PT Lowered to $40 at Bernstein; 'Shares Still Undervalued'

Feb 24, 2026 11:49AM Beam Therapeutics Inc (BEAM) PT Raised to $47 at BofA Securities

Feb 20, 2026 06:46AM Canaccord Genuity Starts Beam Therapeutics Inc (BEAM) at Buy

Jan 21, 2026 07:44AM Beam Therapeutics Inc (BEAM) PT Raised at Bernstein Following Positive Regulatory Update

Jan 15, 2026 06:43AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Jan 12, 2026 07:54AM Beam Therapeutics (BEAM) Reiterated at Overweight by Cantor Fitzgerald

Jan 12, 2026 07:25AM 'Our Top Pick Is Beam Therapeutics Inc (BEAM)'; PT Raised at Bernstein

Jan 12, 2026 04:04AM Beam Therapeutics reaches FDA alignment on accelerated approval pathway

Jan 7, 2026 12:40AM UBS Starts Beam Therapeutics Inc (BEAM) at Neutral

Nov 17, 2025 09:15AM Benchmark Reiterates Speculative Buy Rating on Beam Therapeutics Inc (BEAM)

Nov 4, 2025 03:27PM Beam Therapeutics Inc. (BEAM) spreader of 5K contracts of February 25 and 35 calls as share price down 5.5%

Nov 4, 2025 08:02AM Beam, Inc. (BEAM) Misses Q3 EPS by 5c

Oct 31, 2025 09:54AM FDA Clears Way for Faster Personalized Gene Editing Treatments

Oct 9, 2025 12:12PM Jefferies Starts Beam Therapeutics Inc (BEAM) at Buy

Sep 15, 2025 07:33AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Aug 30, 2025 04:00PM Why public perception matters so much for biotech valuations

Aug 19, 2025 06:56AM Cantor Fitzgerald Reiterates Overweight Rating on Beam Therapeutics Inc (BEAM)

Aug 14, 2025 07:00AM Beam Therapeutics receives FDA RMAT designation for BEAM-101 therapy

Aug 5, 2025 12:49PM Clear Street Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Jul 1, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Jun 18, 2025 12:15PM CRISPR Therapeutics (CRSP) gains on continued chatter

Jun 17, 2025 11:28AM Verve Therapeutics takeover has 'positive readthrough' for gene editing space - BMO Capital

Jun 16, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Jun 13, 2025 07:00AM Beam Therapeutics Inc. (BEAM) Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101

Jun 3, 2025 07:00AM Beam Therapeutics Inc. (BEAM) Granted FDA Orphan Drug Designation for BEAM-101

May 29, 2025 04:02PM Beam Therapeutics (BEAM) Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 12, 2025 04:05PM Beam (BEAM) Announces U.S. FDA RMAT Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 6, 2025 07:36AM Beam, Inc. (BEAM) Misses Q1 EPS by 3c

Apr 22, 2025 03:20PM Beam Therapeutics Inc. (BEAM) 10K contracts of August 20 puts trade

Apr 10, 2025 05:32AM Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'

Apr 7, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Mar 28, 2025 06:19AM BofA Securities Upgrades Beam Therapeutics Inc (BEAM) to Buy

Mar 27, 2025 04:01PM Beam Therapeutics (BEAM) Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency

Mar 25, 2025 09:44AM Bernstein SocGen Group Reiterates Outperform Rating on Beam Therapeutics Inc (BEAM)

Mar 15, 2025 04:00PM Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma

Mar 13, 2025 04:26AM Beam Therapeutics Inc (BEAM) PT Raised to $64 at Citi

Mar 11, 2025 10:22AM Bernstein Reiterates Outperform on Beam Therapeutics Inc (BEAM) Amid Positive AATD Data

Mar 11, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Mar 10, 2025 12:59PM Jones Trading Upgrades Beam Therapeutics Inc (BEAM) to Buy

Mar 10, 2025 12:58PM Mizuho Reiterates Outperform Rating on WAVE Life Sciences (WVE)

Mar 10, 2025 11:36AM Scotiabank Upgrades Beam Therapeutics Inc (BEAM) to Sector Outperform

Mar 10, 2025 06:24AM Beam Therapeutics Inc. (BEAM) Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency

Mar 10, 2025 06:22AM Beam Therapeutics Inc. (BEAM) Prices 16.15M Share Offering at $28.48/sh

Mar 3, 2025 06:55AM Beam Therapeutics Inc (BEAM) PT Raised to $25 at Scotiabank

View Older Stories